Nontuberculous mycobacterial (NTM) lung disease is a chronic, progressive condition caused by nontuberculous mycobacteria. NTM lung disease occurs more frequently in older adults and people with other lung diseases, like bronchiectasis, and chronic obstructive pulmonary disease (COPD).
Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2
Bronchiectasis is a chronic, progressive lung condition affecting infants, children and adults. While the global prevalence of bronchiectasis is not accurately known,1 there is a growing awareness of the disease.2
If you suffer from Chronic Obstructive Lung Disease (COPD), simple tasks can start to feel larger than life. While there is no cure, there are steps you can take to improve your health and quality of life.
If you suffer from Chronic Obstructive Lung Disease (COPD), simple tasks can start to feel larger than life. While there is no cure, there are steps you can take to improve your health and quality of life.
Have you ever struggled with chest congestion or a buildup of mucus in your chest? If so, you're not alone. Many people experience these uncomfortable symptoms, which can be caused by a variety of factors such as the common cold, allergies, asthma or COPD. The article below explores the role of mucus in chest congestion and discuss some ways to clear your airways.
The most efficient and effective delivery method remains that recommended in the device IFU (one actuation inhaled at a time, as well inhalation as soon as possible after actuation)
However, this laboratory-based study has indicated that a modified common-canister protocol with an anti-static VHC as the aerosol transfer vehicle has the potential to be a viable ‘off-label’ proposition in hospital situations where there is an urgent need to conserve pMDI medication as well as avoid cross-contamination from pathogenic viruses or bacteria
The DPI results suggest that inhalation breathing profiles can have an appreciable impact upon aerosol delivery, with one participant having much less predicted medication as fine particles
In contrast, although the inhalation profiles across all participants were also divergent when asked to inhale from the pMDI + VHC, either tidal breathing or by a slow, deep inhalation, all volunteers would have received a relatively consistent amount of medication.
It also appears that the pMDI + VHC platform delivers a larger FPM<5.0 µm for both APIs and a consequently smaller coarse particle mass. However, it is recognized that more investigation is warranted with a larger number of volunteers and with other passive DPIs having different resistances
Have you ever struggled with chest congestion or a buildup of mucus in your chest? If so, you're not alone. Many people experience these uncomfortable symptoms, which can be caused by a variety of factors such as the common cold, allergies, asthma or COPD. The article below explores the role of mucus in chest congestion and discuss some ways to clear your airways.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
This article describes the generative, patient-centered, design process used in the development of a prototype VHC intended primarily for use ‘on the go’ by adults with persistent asthma or newly diagnosed COPD.
Various improvements have been made to the basic jet nebulizer design with the intent of delivering more medication to the distal airways while still providing aerosol within the respirable range of 3 – 5 μm.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
Bronchiectasis is a chronic, progressive lung condition affecting infants, children and adults. While the global prevalence of bronchiectasis is not accurately known,1 there is a growing awareness of the disease.2
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
